4 research outputs found

    Assessment of salivary and serum antioxidant status in patients with recurrent aphthous stomatitis

    Get PDF
    Objective: The aim of this study was to determine the possible association of oxidant/antioxidant status and recurrent aphthous stomatitis (RAS). Study design: The study consis ted of thirty-one patients with RAS and thirty-two healthy controls from whom saliva and blood samples were collected. Superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and catalase (CAT) were measured in erythrocytes and total antioxidant status (TAS) was measured in plasma and saliva. Results: Erythrocyte SOD activity was significantly lower in RAS patients in comparison to healthy controls (P=0.012). No significant differences were found in erythrocyte GSHPx, CAT activities, and salivary and plasma TAS between RAS patients and control subjects (p>0.1). Conclusion: Changes in SOD activity may be important in the inflammatory reactions observed in RAS, but other tested defense systems such as CAT and GSHPx do not seem to play a primary role in the aetiopathogenesis of RAS. Moreover, the antioxidant system in saliva and plasma is not as affected as in erythrocytes in RAS patients, and therefore it may not be considered an appropriate indicator of the body?s total antioxidant status

    Benzylidene Barbituric Acid Derivatives Shown Anticonvulsant Activity on Pentylenetetrazole-Induced Seizures in Mice: Involvement of Nitric Oxide Pathway

    Get PDF
    ABSTRACT Background: Barbituric acid derivatives have long been used as central nervous system (CNS) suppressants, such as sedatives, hypnotics and anticonvulsants. In addition, previous studies have implicated the involvement of nitric oxide (NO) in the anticonvulsive effects of barbiturates in CNS. Therefore, the purpose of this study was to figure out the effects of a novel class of barbituric acid derivatives on pentylenetetrazole (PTZ)-induced seizures in male mice. Methods: Thirteen synthesized barbituric acid derivatives (a-m) and phenobarbital were administered intraperitoneally (i.p.) 30 min before induction of seizures by PTZ administration. The mechanisms of PTZ-induced seizures in the mice was evaluated using a non-selective nitric oxide synthase (NOS) inhibitor, selective inducible NOS (iNOS) inhibitor, a selective neuronal NOS (nNOS) inhibitor, and NO substrate. Results: Administration of most of the above mentioned derivatives significantly increased the seizures threshold (P<0.001). The most potent derivative (compound a), was chosen in order to investigate the mechanism of action involving in anticonvulsant activity. Administration of a non-selective NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME) and a selective nNOS inhibitor, 7-nitroindazole (7-NI) reversed anticonvulsant activity of compound a. However, injection of the nitric oxide precursor, L-arginine (L-Arg) and a selective iNOS inhibitor, aminoguanidine (AG), did not change anticonvulsant activity of the mentioned compound. Conclusion: These results indicated that the NO system, specifically nNOS may contribute to the anticonvulsant activity of benzylidene barbituric acid derivative a. Therefore, this compound is a good candidate in order to designing new anticonvulsant medication

    Comparison of the Efficacy of Topical Triamcinolone in Orabase and Curcumin in Orabase in Oral Graft-versus-Host Disease

    No full text
    Objectives: Graft-versus-host disease (GVHD) is among the most frequent complications of allogeneic hematopoietic stem cell transplantation (HSCT). GVHD has several clinical manifestations in the oral cavity, including painful desquamative erythema, ulcerative mucosal lesions, and lichenoid lesions. The patients presenting with oral GVHD complain of oral sensitivity, pain, dysgeusia, and xerostomia. The treatment of oral GVHD includes a proper systemic therapy combined with a good oral hygiene and the use of local and topical steroids. Corticosteroids and immunosuppressants are used for the treatment of chronic oral GVHD; however, they are associated with different complications. Evidence shows that curcumin has anti-inflammatory and antioxidative properties. The treatment of lichen planus and oral mucositis with curcumin has been successful. This study aimed to compare the efficacy of topical curcumin in Orabase and triamcinolone in Orabase in the patients affected by oral GVHD. Materials and Methods: Twenty-six patients presenting with oral GVHD were randomly divided into two groups of 13 using block randomization. The control group used triamcinolone in Orabase, and the case group received curcumin in Orabase. Results: The two groups were not significantly different in terms of the alleviated severity of the lesions at the end of the treatment (P=0.052). The comparison of the pain score via the visual analog scale (VAS) at the onset of the treatment and at days 14 and 28 (completion of the treatment) showed no significant difference between the two groups (P>0.05). Conclusions: Curcumin has comparable efficacy to that of triamcinolone and may be prescribed for the patients presenting with oral GVHD
    corecore